Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “ALK Gene Rearrangement or ROS1 Gene Rearrangement”

11 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 11 of 11 results

Testing effectiveness (Phase 2)Study completedNCT04042558
What this trial is testing

A Study Evaluating Platinum-Pemetrexed-Atezolizumab (+/-Bevacizumab) for Patients With Stage IIIB/IV Non-squamous Non-small Cell Lung Cancer With EGFR Mutations, ALK Rearrangement or ROS1 Fusion Progressing After Targeted Therapies

Who this might be right for
NSCLC Stage IIIBNSCLC Stage IVEGFR Gene Mutation+2 more
Centre Francois Baclesse 150
Early research (Phase 1)Looking for participantsNCT05681780
What this trial is testing

Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC

Who this might be right for
Non Small Cell Lung CancerStage IV Non-small Cell Lung CancerRecurrent Non Small Cell Lung Cancer
H. Lee Moffitt Cancer Center and Research Institute 20
Early research (Phase 1)Study completedNCT05055232
What this trial is testing

A Phase I Study of XZP-3621 in Chinese Patients With ALK or ROS1 Rearrangement Non-small Cell Lung Cancer

Who this might be right for
ROS1 Rearrangement Non-small Cell Lung CancerALK Rearrangement Non-small Cell Lung Cancer
Xuanzhu Biopharmaceutical Co., Ltd. 114
Early research (Phase 1)Ended earlyNCT04005144
What this trial is testing

Brigatinib and Binimetinib in Treating Patients With Stage IIIB-IV ALK or ROS1-Rearranged Non-small Cell Lung Cancer

Who this might be right for
ALK Gene RearrangementLung Non-Small Cell CarcinomaProgressive Disease+6 more
University of California, San Francisco 3
Not applicableStudy completedNCT03718117
What this trial is testing

Descriptive Observational Study ALK-2016-CPHG

Who this might be right for
NSCLCCrizotinibALK Gene Rearrangement or ROS1 Gene Rearrangement
Pfizer 73
Early research (Phase 1)Study completedNCT00585195
What this trial is testing

Oral PF-02341066, A C-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer

Who this might be right for
Non-Small Cell Lung Cancer ALK-positiveNon-Small Cell Lung Cancer c-Met DependentNon-Small Cell Lung Cancer ROS Marker Positive+2 more
Pfizer 596
Testing effectiveness (Phase 2)Looking for participantsNCT03093116
What this trial is testing

Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements

Who this might be right for
Locally Advanced Solid TumorsMetastatic Solid Tumors
Turning Point Therapeutics, Inc. 500
Testing effectiveness (Phase 2)WithdrawnNCT03164694
What this trial is testing

APatinib Plus Chemotherapy vErsus Chemotherapy As First-line Treatment for Advanced NSCLC

Who this might be right for
Lung Cancer
Sun Yat-sen University
Testing effectiveness (Phase 2)Active Not RecruitingNCT02568267
What this trial is testing

Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)

Who this might be right for
Breast CancerCholangiocarcinomaColorectal Cancer+13 more
Hoffmann-La Roche 534
Early research (Phase 1)Active Not RecruitingNCT02321501
What this trial is testing

Ceritinib and Everolimus in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIB-IV Non-small Cell Lung Cancer

Who this might be right for
ALK PositiveLocally Advanced Malignant Solid NeoplasmMetastatic Malignant Solid Neoplasm+3 more
M.D. Anderson Cancer Center 37
Testing effectiveness (Phase 2)Active Not RecruitingNCT02650401
What this trial is testing

Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options

Who this might be right for
Solid TumorsCNS Tumors
Hoffmann-La Roche 69